Speech-Language Pathologists in Jenkintown, PA Accepting Medicare

10 Speech-Language Pathologists found. Showing 1 - 10

Emily Goldblum Marks, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1072 Sparrow Rd, Jenkintown, PA 19046 Phone: 412-901-3990

Kathryn Mcdonald, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 261 Old York Rd, Jenkintown, PA 19046 Phone: 215-887-5748

Robert Neidich, CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 111 Walnut St, Jenkintown, PA 19046 Phone: 215-913-3799

Maggie Fitchett Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 500 York Rd Ste 250, Jenkintown, PA 19046 Phone: 215-572-5300

Joanna Clancy Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 606 Shoemaker Ave, Jenkintown, PA 19046 Phone: 215-512-8480

Lauren Maureen Zielenbach, MA CCC SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 310 Evergreen Rd, Jenkintown, PA 19046 Phone: 215-870-3536

Cassandra Calia Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 500 York Rd Ste 200, Jenkintown, PA 19046 Phone: 215-884-1128

Mrs. Maya Victoria Cheek, MS., CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 614 Washington Ln, Jenkintown, PA 19046 Phone: 215-884-4227

Layne M Munson, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 500 Old York Rd., Suite 260, Jenkintown, PA 19046 Phone: 215-884-1128    Fax: 215-885-2123

Bilingual Brain Inc. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 610 Old York Road Suite 400, Jenkintown, PA 19027 Phone: 267-576-5078

News Archive

Merck's GARDASIL receives approval from FDA Advisory Committee

Merck & Co., Inc. announced today that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee agreed that efficacy, immunogenicity and safety data from clinical trials in males support the use of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] in boys and men 9 through 26 years of age for the prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11.

Screening system spots cancerous changes invisible to sequencing

A technique that can identify causes of cancer invisible to genetic sequencing has uncovered large sets of previously unknown pancreatic cancer genes. It is hoped that this study will boost research into a disease that is still poorly understood and for which five-year survival rates have stood at around 5 per cent for the past four decades.

Advantagene reaches SPA agreement with FDA for ProstAtak Phase 3 trial to prevent prostate cancer recurrence

Advantagene, Inc., a Massachusetts-based biopharmaceutical company, announced today that it reached an agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment (SPA) for a pivotal Phase 3 clinical trial of ProstAtak™, its lead agent for patients with newly diagnosed prostate cancer.

Study looks at the impact of COVID-19 lockdown on pediatric emergency admissions

Decreases in hospital attendances and admissions amid fears of COVID-19 may result in avoidable harm for under 16s say researchers, who warn against the "unintended consequences of pandemic control measures".

Read more Medical News

› Verified 3 days ago